Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Furmonertinib in First-line EGFR Mutated NSCLC with CNS Metastases
NCT05379803Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival at 26 months. Started May 2022; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05379803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379803.